The press release of Dr. Wiestner of the NIH on the one year data on single agent ibrutinib with no other drugs to help in 17p del and > 65 patients, with my commentary: bkoffman.blogspot.com/2013/...
Bottom line: 94% event free survival at one year. WOW!
iwCLL 2019 | Five-year follow up of the UK CLL Forum ibrutinib data
Dr Sharman's thoughts on the race for FDA Approval for Obinituzumab, Ibrutinib and Idelalisib Lessons from five years of ibrutinib experience
ASH 2018: Professor Peter Hillmen on the Combination of Ibrutinib and Obinutuzumab in CLL: Timing MattersASH 2018: Dr. Chadi Nabhan on the Cost of Ibrutinib vs. Chemo vs Chemoimmunotherapy in CLL and on way too much chemo being used.
